<span item_type="fundamental" item_id="693d5917a780cf354e699b45b7b32eb7" counter_id="ST/US/STSSW" env="prod"></span><span item_type="announcement" item_id="516465363794596481" env="prod"></span><p>EPS: As of FY2025 Q1, the actual value is USD 38.62.</p><p></p><h3>Segment Revenue</h3><ul><li>The company has not generated any revenue to date.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1737995/000164117225010894/form10-q.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Net Income (Loss)</strong>: For the three months ended March 31, 2025, the company reported a net income of $1,928,834, compared to a net loss of - $982,386 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1737995/000164117225010894/form10-q.htm"></span></li><li><strong>Research and Development Expenses</strong>: Decreased to $82,016 in 2025 from $197,439 in 2024, a reduction of $115,423 or 58%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1737995/000164117225010894/form10-q.htm"></span></li><li><strong>General and Administrative Expenses</strong>: Increased to $1,939,753 in 2025 from $1,646,613 in 2024, an increase of $293,140 or 18%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1737995/000164117225010894/form10-q.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Net Cash Used in Operating Activities</strong>: - $2,450,564 for the three months ended March 31, 2025, compared to - $1,889,315 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1737995/000164117225010894/form10-q.htm"></span></li><li><strong>Net Cash Used in Investing Activities</strong>: - $473,658 in 2025, compared to - $2,852 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1737995/000164117225010894/form10-q.htm"></span></li><li><strong>Net Cash Provided by Financing Activities</strong>: $13,953,031 in 2025, compared to $396 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1737995/000164117225010894/form10-q.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Warrant Liability</strong>: As of March 31, 2025, the warrant liability was $7,781,658, compared to $98,913 as of December 31, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1737995/000164117225010894/form10-q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: The company is committed to driving revenue growth from Securegard and Sologard projects in 2025, with production on track for a transition to revenue in the second half of 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1737995/000164117225010894/form10-q.htm"></span></li><li><strong>Non-Core Business</strong>: The company continues to work towards amending the Asset Purchase Agreement with Nephron and InjectEZ, LLC, with the closing contingent on obtaining further amendments and necessary financing.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1737995/000164117225010894/form10-q.htm"></span></li></ul>

SHARPS TECHNOLOGY INC C/WTS (TO PUR COM) | 10-Q: FY2025 Q1 EPS: USD 38.62